Optinose (OPTN): Price to Sales

Symbol and logo of brand Optinose (OPTN)

The price-to-sales ratio for OptiNose, Inc. (OPTN) highlights margin risks stemming from generic competition and marketing expenses, while 1.20 reflects the latest value of this metric. OptiNose, Inc. (OPTN) generates revenue through the sale of patented systems for nasopharyngeal therapy. Operations are strictly regulated by FDA standards, which limits the environmental footprint solely to the disposal of biomaterials.

OptiNose Corp (OPTN) - Market Cap to Revenue from 07/04/2022 to 05/31/2025

Metric breakdowns and analytics for Optinose (OPTN)

- share price and consensus valuation forecast:
Price Performance Chart optinose.com|OPTN - Price Target Chart
- stock exchange capitalization data:
Market Value Optinose|OPTN - Total Company Value
- shareholders' equity book value data:
Share Book Value OptiNose|OPTN - Company Net Assets|Market Cap to Book Value Multiple optinose.com|OPTN - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient OptiNose, Inc.|OPTN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio OptiNose Corp|OPTN - Company Debts|Debts to Book Value Optinose|OPTN - Company Long-Term Debt|Short-Term Debt Volume OptiNose|Immediate Liquidity optinose.com
- earnings and valuation multiples indicators:
OPTN - Net Income|Expected Net Income OptiNose, Inc.|OPTN - P/E Multiple|Market Cap to Projected Earnings OptiNose Inc|OPTN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Optinose|OPTN - Operating profit EBITDA|Net earnings per share for the last 12 months OptiNose|OPTN - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months optinose.com|OPTN - Earnings per share growth in current year|Expected net earnings per share growth next year OptiNose, Inc.
- sales revenue and business income indicators:
OPTN - Company Revenue|Company Expected Revenue optinose.com|OPTN - Market Cap to Revenue|Price to Expected Revenue Ratio Optinose
Fundamental company analysis:OPTN - optinose.com
Core merchandise of optinose.com

The P/S ratio determines the market value of a business relative to its annual sales volume, measuring the premium investors are willing to pay per unit of revenue. The capitalization-to-revenue trend reflects the efficiency of OptiNose, Inc. (OPTN) asset monetization amid aggressive marketing and generic pressure, where high costs to capture market share in nasal sprays may temporarily distort the company's fundamental valuation.

Competitors of OptiNose, Inc.

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|Verona Pharma PLC (VRNA) - Price to Sales|MENS - Price-to-Revenue Ratio|Price-to-Sales Ratio LGND|AMRX (Amneal Pharmaceuticals) - Market Cap to Revenue|PRGO: Market Cap to Sales Volume|ALVO (Alvotech SA) - P/S Multiple|Liquidia Corp (LQDA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANI Pharmaceuticals Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio MannKind Corporation MNKD|amphastar.com (AMPH) - Price to Sales|PCRX - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ARS Pharmaceuticals Inc SPRY|TBPH: P/S Multiple|Price to Sales Aquestive Corp (AQST)|Market Cap to Revenue SCPH|TECX: Market Capitalization-to-Revenue Ratio|P/S Multiple TNXP|Price-to-Revenue Coefficient sxtchina.com|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BHST: Market Cap to Revenue Ratio|eXoZymes Inc - P/S Multiple|Oramed Pharmaceuticals (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|HYFT - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ABVC BioPharma Inc|Price to Sales Cumberland Corp CPIX|Price-to-Revenue Ratio Quantum BioPharma Ltd (QNTM)|FGEN: Price-to-Sales Ratio|Telomir Pharmaceuticals, Inc. - Market Cap to Revenue|Market Cap to Sales Volume RANI (Rani Therapeutics Holdings)|SNYR - Price-to-Revenue Ratio|RLYB (Rallybio Corporation) - Market Cap to Revenue Ratio|lexariabioscience.com (LEXX) - Price-to-Revenue Ratio|Price-to-Sales Ratio PULM (pulmatrix.com)|PTHL (Pheton Holdings Limited) - P/S Multiple|APM: Market Capitalization-to-Revenue Ratio|P/S Multiple LYRA|P/S Multiple Impact BioMedical, Inc. (IBO)|Price-to-Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|Market Capitalization-to-Revenue Ratio YCBD|PRFX - Price-to-Revenue Ratio|Altamira Therapeutics (CYTO) - Market Cap to Revenue|LIPO: P/S Multiple|Pieris Pharma (PIRS) - P/S Multiple|Market Cap to Revenue PROC|PTPI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Qilian International Holding (QLI)|SLRN - Price to Sales|TFF Pharma - Market Cap to Revenue